2024-10-26 - Analysis Report
## Regeneron Pharmaceuticals Inc (REGN) Stock Analysis Report

**Overview:** Regeneron Pharmaceuticals Inc is a biotechnology company that focuses on the discovery, development, and commercialization of innovative medicines for serious diseases.

**Performance Analysis:**

**1. Performance Comparison:**

* **Cumulative Return:** 77.83%
* **S&P 500 (VOO) Cumulative Return:** 135.48%
* **Performance Gap:** -57.65% (Relative Gap: 21.29%)
* **Interpretation:** REGN has underperformed the S&P 500 by 57.65%. This means its cumulative return has been significantly lower compared to the benchmark index. However, its relative gap of 21.29% indicates that it is still within the upper range of historical underperformance. 

**2. Recent Price Movements:**

* **Closing Price:** 928.9 (Last-market: 933.25)
* **5-day Moving Average:** 959.5
* **20-day Moving Average:** 1004.61
* **60-day Moving Average:** 1095.54
* **Interpretation:** REGN's stock is trading below all three moving averages, indicating a potential downtrend. The price is approaching the 5-day moving average, suggesting potential short-term support.

**3. Technical Indicators:**

* **RSI:** 22.36
* **PPO:** -0.47
* **Delta_Previous_Relative_Divergence (20-day):** -17.59 (-) 
* **Expected Return:** 0.0%
* **Interpretation:** Both RSI and PPO are in oversold territory, suggesting the stock might be undervalued. The negative divergence indicates that the stock is likely to continue its downward trajectory. 
* **However, the Last-market price (933.25) is slightly above the closing price (928.9), indicating a slight upward movement. This might be a positive signal and could indicate a potential bounce back.

**4. Recent Earnings and Outlook:**

| Date        | EPS     | Revenue    |
|-------------|---------|------------|
| 2024-08-01 | 13.25   | 3.55 B$    |
| 2024-05-02 | 6.7     | 3.15 B$    |
| 2023-11-02 | 9.48    | 3.36 B$    |
| 2023-08-03 | 9.05    | 3.16 B$    |
| 2024-08-01 | 9.05    | 3.16 B$    |

* **Analysis:** Recent earnings have been mixed, with strong growth in revenue but some volatility in EPS. The most recent earnings were released on 2024-08-01, and it remains unclear if it met or exceeded analysts' estimates. 

**5. News and Recent Issues:**

* **Latest Earnings News:**  Please provide the specific news sources (e.g., shacknews) or date of the earnings release to obtain and analyze the latest news related to Regeneron's earnings. 
* **Recent Market Outlook:** A thorough analysis requires access to specific financial platforms and data. Please provide more specific questions or information regarding the market outlook, analyst opinions, and performance highlights. 

**6. Overall Analysis:**

Regeneron Pharmaceuticals Inc (REGN) is currently experiencing a period of underperformance compared to the S&P 500. The stock is trading below its moving averages and technical indicators suggest a potential downtrend. However, it's important to note that the recent slight upward movement in the stock price might indicate a potential bounce back. 
The mixed earnings results are another factor to consider. 
A deeper analysis of recent news and analyst opinions is necessary for a comprehensive understanding of the company's current outlook. 

**7. Recommendations:**

Based on the current data, REGN presents a potential investment opportunity for long-term investors seeking exposure to the biotechnology sector. However, the current market conditions and recent underperformance require a cautious approach.  
It is recommended to conduct further research, consult with financial advisors, and stay updated on the company's news and developments before making any investment decisions.
